Pembrolizumab (Keytruda)

  • 149 replies
  • 37 subscribers

I read this morning that NHS England have secured a deal with the manufacturer of the immunotherapy drug Pembrolizumab (marketed under the brand name Keytruda) for early stage TNBC. Currently it is used further down the path for people with unresectable secondaries where chemo hasn’t removed the cancer. It is a targeted therapy for tumours expressing PD-L1, so not all cases of TNBC will benefit.